logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Discover
PRAX
Praxis Precision Medicines, Inc.
319.60
2 x 337.47
1 x 321.69
bid
ask
-
15.19
4.54%
2 @ 04:16 AM
374.00 +54.40 (17.02%)
Ytd8.43%
1y640.33%
312.05
day range
337.72
37.19
52 week range
366.52
Open330.89Prev Close334.79Low312.05High337.72Mkt Cap8.91B
Vol607.03KAvg Vol494.92KEPS-13.39P/EN/AForward P/E-35.69
Beta2.75Short Ratio7.27Inst. Own116.85%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning05-0750-d Avg314.75200-d Avg256.511yr Est619.78

PRAX News

benzinga.com
Praxis Precision Medicines Announces FDA Extends PDUFA Date To December 27, 2026 For Relutrigine Fol

FDA sets updated PDUFA date of December 27, 2026BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Pre

Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies
globenewswire.com
Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN

FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Pr

Applied Materials To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday
benzinga.com
Applied Materials To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts upgraded and downgraded several top companies, including Applied Materials,
benzinga.com
Needham Maintains Buy on Praxis Precision Medicine, Raises Price Target to $575

Needham analyst Ami Fadia maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises

Praxis' Seizure Drug Move Towards Faster Development After Positive Trial Results
benzinga.com
Praxis' Seizure Drug Move Towards Faster Development After Positive Trial Results

FDA grants Breakthrough Therapy Designation to Praxis' elsunersen after strong seizure reduction
benzinga.com
Praxis Precision Medicines Receives Breakthrough Therapy Designation From FDA For Elsunersen To Trea

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system

benzinga.com
RBC Capital Initiates Coverage On Praxis Precision Medicine with Outperform Rating, Announces Price

RBC Capital analyst Leonid Timashev initiates coverage on Praxis Precision Medicine (NASDAQ:PRAX)
benzinga.com
Oppenheimer Maintains Outperform on Praxis Precision Medicine, Lowers Price Target to $650

Oppenheimer analyst Jay Olson maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform
benzinga.com
Truist Securities Maintains Buy on Praxis Precision Medicine, Lowers Price Target to $616

Truist Securities analyst Danielle Brill maintains Praxis Precision Medicine (NASDAQ:PRAX) with a
benzinga.com
Deutsche Bank Maintains Buy on Praxis Precision Medicine, Lowers Price Target to $374

Deutsche Bank analyst David Hoang maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy an
benzinga.com
Wedbush Maintains Underperform on Praxis Precision Medicine, Lowers Price Target to $162

Wedbush analyst Laura Chico maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Underperform

CrowdStrike To Gain 7%? Here Are 10 Top Analyst Forecasts For Tuesday
benzinga.com
CrowdStrike To Gain 7%? Here Are 10 Top Analyst Forecasts For Tuesday

Wall Street analysts change ratings for top stocks: CRWD price target raised, FULC target lowered, H
benzinga.com
Baird Maintains Outperform on Praxis Precision Medicine, Lowers Price Target to $400

Baird analyst Joel Beatty maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform and

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com
HC Wainwright & Co. Maintains Buy on Praxis Precision Medicine, Lowers Price Target to $1201

HC Wainwright & Co. analyst Douglas Tsao maintains Praxis Precision Medicine (NASDAQ:PRAX) wi

Praxis Reassesses Vormatrigine Program After Pivotal Epilepsy Study Misses Primary Endpoint
benzinga.com
Praxis Reassesses Vormatrigine Program After Pivotal Epilepsy Study Misses Primary Endpoint

Praxis Precision Medicines reports mixed Phase 2/3 POWER1 results for vormatrigine, with higher-dose
benzinga.com
BTIG Maintains Buy on Praxis Precision Medicine, Lowers Price Target to $810

BTIG analyst Kambiz Yazdi maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and lowers

12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com
Praxis Precision's Phase 2/3 POWER1 Study Of Vormatrigine In Focal Onset Seizures Did Not Meet Its P

POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary succes